We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Coffee Drinkers Have Lower Risk of Getting Autoimmune Liver Disease

By LabMedica International staff writers
Posted on 29 May 2013
Print article
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, according to new research.

The new findings were presented May 2013 at the Digestive Disease Week 2013 Conference, held in Orlando (FL, USA). PSC is an inflammatory disease of the bile ducts that results in inflammation and subsequent fibrosis that can lead to cirrhosis of the liver, biliary cancer, and liver failure.

“While rare, PSC has extremely detrimental effects,” said study author Craig Lammert, MD, a Mayo Clinic (Rochester, MN, USA) gastroenterologist. “We’re always looking for ways to mitigate risk, and our first-time finding points to a novel environmental factor that also might help us to determine the cause of this and other devastating autoimmune diseases.”

The study examined a large group of US patients with PSC and primary biliary cirrhosis (PBC) and a group of healthy patients. Data showed that coffee consumption was linked with a lower risk of PSC, but not PBC. PSC patients were much apt not to drink coffee than healthy patients were. The PSC patients also spent almost 20% less of their time routinely drinking coffee than the control group.

The study suggests PSC and PBC vary more than originally believed. Konstantinos Lazaridis, MD, a Mayo Clinic hepatologist and senior author of the study, remarked, “Moving forward, we can look at what this finding might tell us about the causes of these diseases and how to better treat them.”

Related Links:

Mayo Clinic


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.